Home » Genta Receives Orphan-Drug Designation for Leukemia Candidate
Genta Receives Orphan-Drug Designation for Leukemia Candidate
The FDA has granted orphan-drug designation to Genta for its drug candidate LR3001, a compound intended to treat chronic myelocytic leukemia.
The drug has already been tested in two Phase I clinical trials in patients with myeloid leukemia, and Genta said it plans to pursue further clinical development of the compound in patients with both hematologic cancers and solid tumors.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May